Tag:

Eli Lilly

Latest Headlines

Latest Headlines

Lilly inks a $456M oncology deal with China's Innovent

In a second major bet on Asian R&D, Eli Lilly has signed a $456 million partnership with China's Innovent Biologics to collaborate in oncology, mixing and matching assets with hopes of finding success in each company's home country.

Lilly and China's Innovent Biologics tie up on cancer drug candidates with $56M upfront

Eli Lilly & Co. and China's Innovent Biologics agreed to co-develop at least three experimental cancer drugs--including one from Lilly's research labs and two from Innovent--in a deal that will see the Indianapolis-based company pay $56 million upfront.

Big Pharma's market cap stars of 2014: Lilly, AbbVie, AstraZeneca

Who can resist a numbers match-up? Not us, obviously. Even better when the winners are a bit unexpected. Today, it's market cap, courtesy of EvaluatePharma and its annual state of the industry report.

Lilly inks a $690M deal to get its hands on an autoimmune drug

Eli Lilly is betting up to $690 million that a drug from Korea's Hanmi Pharmaceutical can successfully treat an array of autoimmune diseases, licensing an early-stage candidate with ambitious plans for future trials.

German court deals another EU patent blow to Lilly's blockbuster Alimta

It's more bad news for Eli Lilly's Alimta in Europe. After losing a patent fight last year with Actavis in England, the Indianapolis drugmaker has now lost another in Germany, paving the way for knockoff versions of its top drug there.

Hutchison China MediTech eyes first modern drug approval in China next year with Eli Lilly candidate

Hutchison China MediTech, based in Hong Kong, expects to file for its first drug approval next year for what it said would be the first modern drug developed in China since artemisinin was developed in the 1970s to treat malaria.

Denovo Biopharma eyes China trial of licensed Eli Lilly neuroscience drug

Denovo Biopharma will conduct clinical trials in China for its exclusively licensed pomaglumetad methionil, a late-stage neuroscience drug licensed from Eli Lilly.

Singapore's TauRx notes Alzheimer's candidate journal publication, but buzz eludes

Phase II results of the first clinical trial of a tau aggregation inhibitor for Alzheimer's disease were published last month in the Journal of Alzheimer's Disease, with Singapore-based TauRx Pharmaceuticals saying it was an important milestone as it moves to report top line results from a Phase III study in 2016.

With peglispro shunted aside, Lilly could go full-tilt after Lantus

Eli Lilly's long-acting basal insulin peglispro is on the back burner now. Some analysts figure it's well on its way to being canned. But the news isn't quite as bad for Lilly as one might expect--nor quite as good for the drug peglispro was hoping to challenge, Sanofi's Lantus.

Is a weak Eli Lilly ripe for a takeover?

Everybody sees something different when they look at Eli Lilly, which has recently dropped out of the top 10 pharma group. A number of analysts, some with good reason to shine up to CEO John Lechleiter, see a company that has hit bottom and is on the comeback trail, with new drug approvals to help bolster Lechleiter's bullish forecasts.